Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

0.92
USD
-0.02
(-2.05%)
-1.17EPS
313.94MMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.31
0.99
0.84
0.87
0.87
1.07
1.09
1.43
0.97
0.76
- -
- -
- -
- -
Basic EPS, GAAP
-1.12
-1.4
-0.67
-0.86
-1.12
-1.22
-0.77
-0.51
-0.33
-0.51
-1.74
-1.23
-1.4
-1.17
Free Cash Flow per Basic Share
-0.89
-0.77
-0.67
-0.8
-1.14
-1.1
-0.82
-0.58
-0.31
-0.56
-1.42
-1.13
-1.29
-1.32
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.55
4.38
3.78
2.98
1.93
0.89
1.14
0.83
4.75
4.31
2.67
4.11
2.78
2.58
Tangible Book Value per Share
1.49
4.34
3.75
2.95
1.89
0.86
1.12
0.81
4.74
4.31
0.03
3.41
2.25
2.23
Basic Weighted Avg Shares
3
4
5
6
6
6
7
7
10
14
27
64
74
105
Sales/Revenue/Turnover
5
4
5
5
5
6
7
10
10
11
- -
- -
- -
- -
Operating Margin (%)
-89.88
-108.75
-94.16
-106.56
-132.51
-113.61
-72.16
-35.91
-34.19
-68.47
- -
- -
- -
- -
Depreciation Expense
1
1
1
- -
- -
- -
- -
- -
- -
- -
1
2
3
4
Net Income, GAAP
-4
-6
-4
-5
-6
-7
-5
-3
-3
-7
-47
-79
-103
-123
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-85.22
-141.24
-79.92
-98.78
-129.43
-113.12
-70.33
-35.6
-33.69
-67.36
- -
- -
- -
- -
Working Capital
4
18
15
13
9
4
6
4
66
57
1
213
120
166
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
- -
2
3
3
3
Total Equity
5
24
21
16
11
5
8
6
67
61
75
291
207
295
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-69.15
-40.72
-16.51
-25.4
-45.72
-85.86
-81.12
-51.59
-9.27
-11.3
-68.17
-43.34
-41.44
-45.78

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
2
2
2
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
114
114
114
Market Capitalization
475
389
314

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
275
242
205
Cash, Cash Equivalents & STI
271
237
202
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
31
37
40
Payables & Accruals
26
29
32
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
126.75%
269.85%
-28.77%
Free Cash Flow
64.96%
125.74%
30.98%
Net Income, GAAP
76.44%
150.61%
30.07%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.18
-0.21
-0.57
-1.23
2025
-0.25
-0.29
-0.35
-0.5
-1.4
2026
-0.25
-0.22
-0.27
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Johan M. Spoor
Full Time Employees
166
Sector
Health technology
Industry
Medical specialties
Address
2401 Elliott Avenue Seattle WA United States 98121
IPO Date
May 31, 2002
Business
Perspective Therapeutics, Inc. (NYSE American: CATX) develops and commercializes precision targeted alpha therapies (TATs) using proprietary Pb-212-based alpha-particle radiopharmaceuticals for cancer treatment in the United States. The company offers image-guided theranostics leveraging chemically matched Pb-203/Pb-212 isotope pairs conjugated to high-affinity tumor-specific peptides via a proprietary Pb-specific chelator; core pipeline candidates include VMT-α-NET in Phase 1/2a for SSTR2-expressing neuroendocrine tumors, VMT01 in Phase 1/2a for MC1R-positive metastatic melanoma, and earlier-stage programs targeting additional solid tumors such as those expressing melanocortin 1 receptor or somatostatin receptors; complementary imaging diagnostics enable tumor visualization and patient selection prior to alpha therapy delivery; a proprietary 212Pb generator supports isotope supply for clinical trials and commercial-scale production. Founded in 1983 and headquartered in Seattle, Washington, the company operates primarily in the radiopharmaceutical sector with ongoing clinical trials at leading academic institutions and expanding manufacturing capabilities across regional facilities. Recent developments include first patient dosing with [212Pb]VMT01 monotherapy at 1.5 mCi in its Phase 1/2a melanoma study in April 2025; dosing of eight patients into Cohort 3 (6.0 mCi) of the VMT-α-NET study within three months of opening in June 2025; presentation of updated interim Phase 1/2a data for VMT-α-NET at ESMO Congress 2025 showing no dose-limiting toxicities in 55 patients and eight confirmed responses in Cohort 2; cash position of $227 million as of December 31, 2024, bolstered by prior fundraising including an $87.4 million private placement in March 2024, funding operations into late 2026 amid scaling of manufacturing sites acquired recently.

Company News

  • Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results

  • Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

  • Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

  • Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

  • Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update

  • Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

  • Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

  • Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research

  • Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

  • Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts

  • Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

  • This $3 Biotech Could Be Worth $11.45, Analyst Says

  • Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

  • Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

  • Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

  • Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

  • Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

  • Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

  • 4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

  • Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP